Topic: antibody drug conjugates
AZ and Daiichi's antibody-drug conjugate nabs FDA priority review; FDA shames Torrent for tainted heart drugs; Takeda sells emerging markets drugs.
Sanofi slims down in Japan. We examine Big Pharma CEOs' Chinese names. Positive data came out from Astellas, Eisai and Chi-Med at ESMO.
Takeda sells meds to Novartis and J&J; Daiichi's AZ-shared HER2 antibody-drug conjugate hits key trial goal; Sun scouts for Chinese partner.
AZ's oncology portfolio jumped 59% in Q1 sales, and China turned up 28% growth. So CEO Pascal Soriot figured its time for some long-term planning.
Nobel laureate wants bigger PD-1 revenue cut; Takeda scouts buyers for Latin America business; Chinese genomics investor is forced out of U.S. firm.
Daiichi is transitioning from CV and metabolic diseases to oncology, and it says now is the right time for a new CEO to take the helm.
Here is some news of note for the week.
Contractor ADC Biotechnology is moving quickly to get a manufacturing facility built in Wales to produce its new ADCs.
Japanese CDMO Ajinomoto Althea is expanding production at its recently completed high-potency products manufacturing facility in San Diego.
Did Daiichi Sankyo receive a buyout bid from AstraZeneca last year? According to the Japanese drugmaker, no.